文献速递浆细胞疾病

BCMA靶向治疗在1-3线复发难治多发性骨髓瘤中的应用

Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.
PubMed 文献 · Blood Adv · 2026-01-01

该综述汇总了近两年在早期复发(1-3线)多发性骨髓瘤中改变实践的BCMA靶向治疗(CAR-T、双特异性抗体、抗体药物偶联物)的3期试验数据。文章探讨了试验特征差异对治疗选择的影响,并讨论了年龄、体能状态、合并症、治疗暴露和可及性等决策因素,以及常见场景下的应用与局限性。

要点

  • BCMA靶向治疗在早期复发多发性骨髓瘤中提供新选择,但试验设计差异增加选择复杂性。
  • 治疗决策需综合考虑年龄、体能、合并症、既往治疗暴露和药物可及性。
  • 共享决策和现实可行性是BCMA靶向治疗应用的重要考量。

核心结论

  • BCMA靶向治疗在早期复发多发性骨髓瘤中显示出改变实践的应用前景,但需结合患者特征和试验差异个体化选择。

研究设计与样本

  • 综述整合了近两年报道的针对1-3线复发难治多发性骨髓瘤的BCMA靶向治疗(CAR-T、双特异性抗体、抗体药物偶联物)的3期试验数据。

主要发现

  • 多项3期试验在早期复发设置中报告了BCMA靶向治疗的结果,涉及CAR-T、双特异性抗体和抗体药物偶联物。
  • 试验在患者人群、设计和现实适用性方面存在差异,增加了治疗选择的复杂性。

临床怎么用

  • 临床决策需考虑年龄、体能状态、合并症、治疗暴露和药物可及性等因素。
  • 在常见临床场景中应评估试验适用性、治疗可及性和后勤因素,并重视共享决策。

局限性

  • 试验特征差异可能影响现实世界适用性,且治疗可及性和后勤考虑可能限制应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment landscape for multiple myeloma is evolving rapidly with the integration of novel B-cell maturation antigen (BCMA)-directed therapies. In the early-relapse setting (1-3 prior lines of therapy), several practice-changing phase 3 trials have reported results in the past 2 years, including chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates. These studies offer exciting new options for clinicians but also introduce complexity due to differences in patient populations, trial designs, and real-world applicability. We synthesize data from trials exploring BCMA-directed immunotherapy in the early-relapse setting, explore nuances in trial characteristics and their implications for treatment selection, and discuss treatment decision determinants, including age, fitness, comorbidities, treatment exposure, and access to therapy. We subsequently discuss how emerging BCMA-directed therapy affects decision-making in several common scenarios. For each of these common scenarios, we explore applicability and limitations from the clinical trials, treatment access, and logistical considerations and the importance of shared decision-making.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hansen DK, Mateos MV, Costa LJ, et al. Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy. Blood Adv. 2026. PMID: 42234936. doi:10.1182/bloodadvances.2026019699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。